Status:
TERMINATED
Efficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
National Science and Technology Council, Taiwan
Conditions:
Glomerulonephritis
Eligibility:
All Genders
20-80 years
Phase:
PHASE3
Brief Summary
We have recently demonstrated that pentoxifylline (PTX) has the potential to treat severe glomerular inflammation in a rat model of accelerated anti-glomerular basement membrane (GBM) glomerulonephrit...
Detailed Description
Corticosteroids and cytotoxic agents such as cyclophosphamide remain the most commonly used regimens for crescentic glomerulonephritis. However, their use is often limited by adverse effects, most not...
Eligibility Criteria
Inclusion
- biopsied-proved crescentic glomerulonephritis, with rapidly progressive renal failure
Exclusion
- Anti-GBM disease, Dialysis-dependency or pulmonary hemorrhage, History of allergy to pentoxifylline, Females are nursing or pregnant, Congestive heart failure, Unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, within the past 6 months prior to signing the informed consent form, Cerebral hemorrhage within the past 6 months prior to signing the informed consent form, Retinal hemorrhage within the past 6 months prior to signing the informed consent form, Known or suspected secondary hypertension, Uncontrolled hypertension or diabetes, Liver cirrhosis or hepatic dysfunction as defined by liver enzymes \> 2 times the upper limit of the normal range, Biliary obstructive disorders, Active malignancy or infection
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT00354198
Start Date
August 1 2006
End Date
June 1 2010
Last Update
November 14 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100